The Global CRM197 Protein Market was valued at USD 92.5 Million in 2024 and is projected to reach USD 142.3 Million by 2030, growing at a Compound Annual Growth Rate (CAGR) of 7.2% during the forecast period (2024–2030). This robust expansion is primarily fueled by the escalating demand for effective conjugate vaccines, rising prevalence of infectious diseases, and significant R&D investments in advanced immunotherapy solutions by leading pharmaceutical companies.

As the biopharmaceutical sector intensifies its focus on targeted and safer vaccine technologies, CRM197—a non-toxic mutant of diphtheria toxin—has emerged as a critical carrier protein. Its unique ability to enhance the immunogenicity of polysaccharide antigens makes it indispensable for modern vaccine development. This blog profiles the Top 10 Companies in the CRM197 Protein Industry, highlighting the key manufacturers and innovators ensuring the global supply chain for this vital biological component.

Download FREE Sample Report:
Global CRM197 Protein Market – View in Detailed Research Report

---

🔟 1. Pfizer Inc.

Headquarters: New York, New York, USA
Key Offering: CRM197 Carrier Protein, Proprietary Conjugate Vaccine Platforms

Pfizer stands as a foundational player in the CRM197 landscape, utilizing the protein as the carrier for its blockbuster pneumococcal conjugate vaccine, Prevnar 13. The company maintains extensive in-house production capabilities for CRM197, ensuring a secure and scalable supply for its global vaccine portfolio and for potential partners through its Centrum for Advanced Technologies.

Innovation and Strategic Focus:

• Pioneer in large-scale GMP manufacturing of CRM197

• Ongoing R&D for next-generation conjugate vaccines targeting additional pathogens

• Strategic partnerships with biotech firms for novel conjugate applications

---

9️⃣ 2. GSK (GlaxoSmithKline plc)

Headquarters: Brentford, London, United Kingdom
Key Offering: CRM197 for R&D and vaccine development

GSK is a global healthcare giant with a formidable vaccines division. While using various carrier proteins, the company actively employs CRM197 in its R&D pipeline for new conjugate vaccines. GSK’s expertise in fermentation and protein purification positions it as a key manufacturer and consumer of high-quality CRM197.

Innovation and Strategic Focus:

• Development of multi-valent conjugate vaccines utilizing CRM197

• Investment in advanced antigen manufacturing technologies

• Focus on expanding vaccine access in emerging markets

---

8️⃣ 3. Merck & Co., Inc.

Headquarters: Kenilworth, New Jersey, USA
Key Offering: CRM197 Protein, Vaccine Adjuvant Systems

Merck leverages its deep biologics manufacturing expertise to produce CRM197 for its internal vaccine programs and external collaborations. The company’s robust quality control and regulatory experience make it a reliable supplier in the high-stakes vaccine market.

Innovation and Strategic Focus:

• Integration of CRM197 in novel oncology and infectious disease candidates

• Process optimization for higher yield and purity of carrier proteins

• Commitment to sustainable and ethical manufacturing practices

---

7️⃣ 4. Sanofi Pasteur

Headquarters: Lyon, France
Key Offering: CRM197-based Conjugate Vaccines, Bulk Antigen Supply

As the vaccines global business unit of Sanofi, Sanofi Pasteur is a major force in immunization. The company utilizes CRM197 in several of its marketed and pipeline vaccines, supported by its state-of-the-art production facilities dedicated to antigen manufacturing.

Innovation and Strategic Focus:

• Leadership in pediatric and influenza conjugate vaccines

• Exploration of CRM197 for non-traditional indications, including allergy therapies

• Active participation in global health initiatives requiring conjugate vaccines

Download FREE Sample Report:
Global CRM197 Protein Market – View in Detailed Research Report

---

6️⃣ 5. Ligand Pharmaceuticals Incorporated

Headquarters: San Diego, California, USA
Key Offering: CRM197 (Captisol® Enabled), Licensing and Royalty Models

Ligand Pharmaceuticals is a prominent biopharmaceutical company known for its Captisol technology, but it also holds valuable intellectual property and capabilities related to CRM197. The company often partners with other firms, providing the carrier protein and technical expertise for conjugate vaccine development.

Innovation and Strategic Focus:

• Partnership-based business model for vaccine development

• Focus on leveraging its protein platform for targeted drug delivery

• Royalty revenue from partners using its proprietary technologies

---

5️⃣ 6. Fina Biosolutions LLC

Headquarters: Rockville, Maryland, USA
Key Offering: High-Purity CRM197, Contract Development & Manufacturing (CDMO)

Fina Biosolutions specializes in the development and manufacturing of conjugate vaccines and their components. The company is a leading pure-play supplier of GMP-grade CRM197, serving biotech and pharmaceutical clients worldwide who are developing their own conjugate vaccine products.

Innovation and Strategic Focus:

• Offers one of the industry’s highest purity CRM197 products

• Provides end-to-end CDMO services for conjugate vaccine manufacturing

• Develops novel conjugation technologies to improve vaccine efficacy

---

4️⃣ 7. Scarab Genomics

Headquarters: Madison, Wisconsin, USA
Key Offering: Reduced Genome E. coli Strains for High-Yield CRM197 Production

Scarab Genomics offers a unique angle in the CRM197 market through its proprietary genome-reduction technology. Its “Clean Genome®” E. coli strains are engineered for superior recombinant protein production, including CRM197, resulting in higher yields and simplified purification processes for manufacturers.

Innovation and Strategic Focus:

• IP-protected bacterial strains optimized for bioproduction

• Focus on reducing production costs and improving efficiency for partners

• Collaborations with vaccine developers to streamline manufacturing

---

3️⃣ 8. Biological E. Limited

Headquarters: Hyderabad, Telangana, India
Key Offering: Cost-effective CRM197, Vaccines for Emerging Markets

Biological E. is a leading Indian vaccines and biologics company with growing capabilities in CRM197 production. It focuses on making life-saving vaccines, including those requiring CRM197, accessible and affordable in low- and middle-income countries, positioning it as a critical supplier for global health organizations.

Innovation and Strategic Focus:

• Strategic focus on supplying the WHO-led pneumococcal conjugate vaccine (PCV) market

• Investment in scaling up antigen manufacturing capacity

• Partnerships with PATH and other global health entities

---

2️⃣ 9. Serum Institute of India Pvt. Ltd.

Headquarters: Pune, Maharashtra, India
Key Offering: High-Volume, Low-Cost Vaccines, Bulk CRM197

As the world’s largest vaccine manufacturer by volume, the Serum Institute of India is a pivotal player. Its massive scale and expertise in producing vaccines for global immunization programs necessitate a reliable supply of key ingredients like CRM197, which it also manufactures to support its expansive conjugate vaccine portfolio.

Innovation and Strategic Focus:

• Unmatched scale and cost-effectiveness in vaccine production

• Critical supplier to Gavi, the Vaccine Alliance, and UNICEF

• Aggressive expansion into new conjugate vaccine development

---

1️⃣ 10. Novartis AG (via Sandoz)

Headquarters: Basel, Switzerland
Key Offering: Biosimilars, Complex Biologics including vaccine components

While Novartis has divested parts of its vaccines business, its biomanufacturing capabilities, now often channeled through its generics division Sandoz, remain substantial. The company possesses the technical know-how for producing complex proteins like CRM197 and is a potential key contractor or supplier in the biosimilars and biologics space.

Innovation and Strategic Focus:

• Expertise in manufacturing and regulatory approval of complex proteins

• Strategic positioning in the growing biosimilars market

• Strong global supply chain and distribution network

Get Full Report Here:
Global CRM197 Protein Market – View in Detailed Research Report

---

🔬 Outlook: The Future of CRM197 Protein Is Synonymous with Advanced Immunization

The CRM197 protein market is intrinsically linked to the future of preventive healthcare. As the global population ages and the threat of antimicrobial resistance grows, the demand for sophisticated, effective vaccines will only intensify. The strategic importance of a reliable, high-quality CRM197 supply chain cannot be overstated.

📈 Key Trends Shaping the Market:

• Expansion of Conjugate Vaccine Applications: Moving beyond pneumococcal and meningococcal diseases to target Group B Streptococcus, Salmonella, and even cancer antigens.

• Rise of Biosimilars and Generics: As patents on blockbuster conjugate vaccines expire, new manufacturers will enter the market, driving demand for CRM197 from CDMOs and suppliers.

• Technological Advancements in Production: Adoption of continuous bioprocessing, high-throughput fermentation, and advanced purification techniques to increase yield, reduce costs, and ensure consistency.

• Focus on Global Health Equity: Increased funding and initiatives from organizations like Gavi and the Bill & Melinda Gates Foundation to develop and distribute affordable conjugate vaccines in developing nations.

The companies profiled above are not just suppliers of a critical protein; they are enablers of global public health, providing the foundational technology that allows for the creation of safer, more effective vaccines that protect millions of lives worldwide.

Get Full Report Here:
Global CRM197 Protein Market – View in Detailed Research Report